Search by Department
Dr. Henry Masur is well known for his expertise in the management of HIV and its comorbidities, and for his expertise in ICU-related infections. His department has published many pivotal studies related to sepsis, the safety of the blood supply, microbial diagnostics, emerging infections, and pulmonary immunology.
Dr. Masur earned his undergraduate degree from Dartmouth College and his medical degree from Cornell University Medical College. He completed his internship and residency in internal medicine at New York Hospital and Johns Hopkins Hospital. Following a fellowship at Cornell in the Division of Infectious Diseases and Internal Medicine, he served as an Instructor and Assistant Professor of Medicine in the Infectious Diseases Division at Cornell from 1978 to 1982.
He was recruited to NIH in 1982 to jointly found a new department of critical care medicine and an HIV/AIDS program with the National Institute of Allergy and Infectious Diseases. He became Chief of the Critical Care Medicine Department in 1989. The Critical Care Medicine Department manages the NIH Clinical Center’s only medical-surgical ICU, emphasizing multidisciplinary care.
CCMD has attained national and international acclaim for its leadership in areas of sepsis, HIV/AIDS, pulmonary immunology, pneumocystis pneumonia, clinical epidemiology, and emerging infections including Ebola and COVID-19. Its senior staff includes national leaders in professional societies and national clinical care guidelines and editorial leaders of major professional society journals.
The department has developed a highly competitive, highly sought training program in critical care medicine which permits candidates to train in pulmonary medicine, infectious diseases, or cardiology as a second subspecialty. The program is led by master teachers who also lead a regional training consortium that takes advantage of the best regional faculty to train ACGME fellows. Its fellowship alumni have leadership positions at academic medical centers across the U.S., as well as leadership roles in professional societies.
Dr. Masur is the founding editor of the NIH-CDC-IDSA Guidelines for Management of Opportunistic Infections in Adults and Adolescents with HIV Infections, Past President, Infectious Diseases Society of America and Senior Associate Editor of Critical Care Medicine. He is the chair of the IDSA Sepsis Task Force and Co-Chair of the NIH COVID-19 Treatment Guideline and the recipient of the 2020 HHS Hubert Humphrey Award for Service to America.
He leads the District of Columbia Partnership for AIDS Progress, a unique collaboration between NIH and the DC government which has created an urban model for decreasing the impact of HIV/AIDS on underserved populations. The program includes the largest urban cohort study of HIV/AIDS in the U.S., and did the first U.S. trials of interferon free therapy of HCV. The program has expanded its focus to new approaches to opioid use disorder with funding from the NIH Office of AIDS Research and the NIH HEAL Program.
Dr. Masur holds clinical appointments at the University of Maryland and the George Washington University School of Medicine.
See his Intramural Research Program bio page.
Rhee C, Chiotos K, Cosgrove SE, Heil EL, Kadri SS, Kalil AC, Gilbert DN, Masur H, Septimus EJ, Sweeney DA, Strich JR, Winslow DL, Klompas M. Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. Clin Infect Dis. 2021 Feb 16;72(4):541-552. doi: 10.1093/cid/ciaa059
Kuriakose S, Singh K, Pau AK, Daar E, Gandhi R, Tebas P, Evans L, Gulick RM, Lane HC, Masur H; NIH COVID-19 Treatment Guidelines Panel. Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Ann Intern Med. 2021 Aug;174(8):1151-1158. doi: 10.7326/M21-1647. Epub 2021 Jun 15. PMID: 34125574 Free PMC article.
Segarra L, Simmens SJ, Castel AD, Kharfen M, Masur H, Greenberg AE. Highly variable trends in rates of newly diagnosed HIV cases in U.S. hotspots, 2008-2017. PLoS One. 2021 Apr 19;16(4):e0250179. doi: 10.1371/journal.pone.0250179. eCollection 2021. Strich JR, Heil EL, Masur H. Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance. J Infect Dis. 2020 Jul 21;222(Suppl 2):S119-S131. doi: 10.1093/infdis/jiaa221.
Rosenthal ES, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, Hill K, Brokus C, D'Amore A, Sidique N, Bijole P, Jones M, Kier R, McCullough D, Sternberg D, Stafford K, Sun J, Masur H, Kottilil S, Kattakuzhy S. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis. 2020 Oct 23;71(7):1715-1722. doi: 10.1093/cid/ciaa105.
Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines IDSA Sepsis Task Force . Clin Infect Dis. 2018 May 2;66(10):1631-1635. doi: 10.1093/cid/cix99
Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017;167:311-318.
Chertow DS, Palmore TN, Masur H. Critical Care Medicine After the 2014-2015 Ebola Outbreak: Are We Ready If It Happens Again? Crit Care Med. 2016 Mar;44(3):457-9.
Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, Kottilil S. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016 Jul;23(7):496-505.
Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis. 2016 Feb 1;62(3):280-288.
Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15;163(12):899-907.
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31;313(12):1232-9.
Visit PubMed.gov for a full list of Dr. Masur's publications.
- HHS Hubert Humphrey Award for Service to America, 2020
- IDSA Edward Kass Lecture, 2018
- Institute of Human Virology-University of Maryland Lifetime Achievement Award, 2018
- John Phillips Award, American College of Physicians, 2010
- President, Infectious Disease Society of America, 2006-2007
- Astute Clinician Lecture, National Institutes of Health, 2002
- American Society for Clinical Investigation
- Association of American Physicians
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 03/16/2022